---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-024352"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:48:43.544143+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital

## Summary
- Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.
- About 972,000 shares outstanding after full exercise of prefunded warrants; outstanding cash-exercisable warrants with strike above market.
- SYMON II clinical study for IL-6 sepsis test progressing; data to support regulatory submission; limited disclosure before submission.
- Manufacturing scale-up and supply-chain initiatives on track for commercialization readiness.
- Company expects to need at least $20M additional capital through end of FY2027, to be raised in tranches.

## SEC filing metadata
- accession: 0001213900-26-024352
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/0001213900-26-024352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/ea0280257-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-024352
- JSON: https://secwatch.observer/filing/0001213900-26-024352.json
- Plain text: https://secwatch.observer/filing/0001213900-26-024352.txt

## Key facts
- Earnings Releases
  Bluejay Diagnostics, Inc. reported the fiscal year ended December 31, 2025 results: net income net losses of approximately $6.8 million.
  - Period: the fiscal year ended December 31, 2025
  - Net income: net losses of approximately $6.8 million
  - Result: reported results
  source text: The Company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, following successful completion of a $3.8 million warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in October 2025. The Company incurred net losses of approximately $6.8 million for the fiscal year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390026024352/0001213900-26-024352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.